335 related articles for article (PubMed ID: 28412211)
1. Serum miR-21 and miR-125b as markers predicting neoadjuvant chemotherapy response and prognosis in stage II/III breast cancer.
Liu B; Su F; Chen M; Li Y; Qi X; Xiao J; Li X; Liu X; Liang W; Zhang Y; Zhang J
Hum Pathol; 2017 Jun; 64():44-52. PubMed ID: 28412211
[TBL] [Abstract][Full Text] [Related]
2. Changes of serum miR34a expression during neoadjuvant chemotherapy predict the treatment response and prognosis in stage II/III breast cancer.
Liu B; Su F; Li Y; Qi X; Liu X; Liang W; You K; Zhang Y; Zhang J
Biomed Pharmacother; 2017 Apr; 88():911-917. PubMed ID: 28178621
[TBL] [Abstract][Full Text] [Related]
3. MicroRNAs miR-7 and miR-340 predict response to neoadjuvant chemotherapy in breast cancer.
Raychaudhuri M; Bronger H; Buchner T; Kiechle M; Weichert W; Avril S
Breast Cancer Res Treat; 2017 Apr; 162(3):511-521. PubMed ID: 28181130
[TBL] [Abstract][Full Text] [Related]
4. Serum microRNA-21 predicted treatment outcome and survival in HER2-positive breast cancer patients receiving neoadjuvant chemotherapy combined with trastuzumab.
Liu B; Su F; Lv X; Zhang W; Shang X; Zhang Y; Zhang J
Cancer Chemother Pharmacol; 2019 Nov; 84(5):1039-1049. PubMed ID: 31482230
[TBL] [Abstract][Full Text] [Related]
5. Circulating miR-34a and miR-125b as Promising non Invasive Biomarkers in Egyptian Locally Advanced Breast Cancer Patients.
Kassem NM; Makar WS; Kassem HA; Talima S; Tarek M; Hesham H; El-Desouky MA
Asian Pac J Cancer Prev; 2019 Sep; 20(9):2749-2755. PubMed ID: 31554373
[TBL] [Abstract][Full Text] [Related]
6. Dynamics of circulating microRNAs as a novel indicator of clinical response to neoadjuvant chemotherapy in breast cancer.
Zhu W; Liu M; Fan Y; Ma F; Xu N; Xu B
Cancer Med; 2018 Sep; 7(9):4420-4433. PubMed ID: 30099860
[TBL] [Abstract][Full Text] [Related]
7. Circulating miR-19a and miR-205 in serum may predict the sensitivity of luminal A subtype of breast cancer patients to neoadjuvant chemotherapy with epirubicin plus paclitaxel.
Li Q; Liu M; Ma F; Luo Y; Cai R; Wang L; Xu N; Xu B
PLoS One; 2014; 9(8):e104870. PubMed ID: 25137071
[TBL] [Abstract][Full Text] [Related]
8. Tissue and Serum miRNA Profile in Locally Advanced Breast Cancer (LABC) in Response to Neo-Adjuvant Chemotherapy (NAC) Treatment.
Al-Khanbashi M; Caramuta S; Alajmi AM; Al-Haddabi I; Al-Riyami M; Lui WO; Al-Moundhri MS
PLoS One; 2016; 11(4):e0152032. PubMed ID: 27064979
[TBL] [Abstract][Full Text] [Related]
9. Downregulation of miR-129 in peripheral blood mononuclear cells is a diagnostic and prognostic biomarker in prostate cancer.
Xu S; Yi XM; Zhou WQ; Cheng W; Ge JP; Zhang ZY
Int J Clin Exp Pathol; 2015; 8(11):14335-44. PubMed ID: 26823749
[TBL] [Abstract][Full Text] [Related]
10. Circulating microRNAs as indicators in the prediction of neoadjuvant chemotherapy response in luminal B breast cancer.
Zhang Z; Zhang H; Li C; Xiang Q; Xu L; Liu Q; Pang X; Zhang W; Zhang H; Zhang S; Duan X; Liu Y; Cui Y
Thorac Cancer; 2021 Dec; 12(24):3396-3406. PubMed ID: 34751517
[TBL] [Abstract][Full Text] [Related]
11. Clinical and biological impact of miR-18a expression in breast cancer after neoadjuvant chemotherapy.
Luengo-Gil G; García-Martínez E; Chaves-Benito A; Conesa-Zamora P; Navarro-Manzano E; González-Billalabeitia E; García-Garre E; Martínez-Carrasco A; Vicente V; Ayala de la Peña F
Cell Oncol (Dordr); 2019 Oct; 42(5):627-644. PubMed ID: 31115881
[TBL] [Abstract][Full Text] [Related]
12. Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial.
Müller V; Gade S; Steinbach B; Loibl S; von Minckwitz G; Untch M; Schwedler K; Lübbe K; Schem C; Fasching PA; Mau C; Pantel K; Schwarzenbach H
Breast Cancer Res Treat; 2014 Aug; 147(1):61-8. PubMed ID: 25086636
[TBL] [Abstract][Full Text] [Related]
13. Serum microRNA-21 expression as a prognostic and therapeutic biomarker for breast cancer patients.
Yadav P; Mirza M; Nandi K; Jain SK; Kaza RC; Khurana N; Ray PC; Saxena A
Tumour Biol; 2016 Nov; 37(11):15275-15282. PubMed ID: 27696295
[TBL] [Abstract][Full Text] [Related]
14. Plasma miRNAs in diagnosis and prognosis of pancreatic cancer: A miRNA expression analysis.
Zhou X; Lu Z; Wang T; Huang Z; Zhu W; Miao Y
Gene; 2018 Oct; 673():181-193. PubMed ID: 29913239
[TBL] [Abstract][Full Text] [Related]
15. [Correlation of metastasis-free survival in patients with breast cancer and changes in the direction of expression of multidrug resistance genes during neoadjuvant chemotherapy].
Litviakov NV; Garbukov EIu; Slonimskaia EM; Tsyganov MM; Denisov EV; Vtorushin SV; Khristenko KIu; Zav'ialova MV; Cherdyntseva NV
Vopr Onkol; 2013; 59(3):334-40. PubMed ID: 23909034
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Significance of Serum miR-22, miR-125b, and miR-15b in Non-Small Cell Lung Cancer Patients.
Shi GL; Zhang XY; Chen Y; Ma S; Bai WQ; Yin YJ
Clin Lab; 2020 Jun; 66(6):. PubMed ID: 32538046
[TBL] [Abstract][Full Text] [Related]
17. Serum Tumor Marker Levels might have Little Significance in Evaluating Neoadjuvant Treatment Response in Locally Advanced Breast Cancer.
Wang YJ; Huang XY; Mo M; Li JW; Jia XQ; Shao ZM; Shen ZZ; Wu J; Liu GY
Asian Pac J Cancer Prev; 2015; 16(11):4603-8. PubMed ID: 26107211
[TBL] [Abstract][Full Text] [Related]
18. Circulating MiR-125b as a marker predicting chemoresistance in breast cancer.
Wang H; Tan G; Dong L; Cheng L; Li K; Wang Z; Luo H
PLoS One; 2012; 7(4):e34210. PubMed ID: 22523546
[TBL] [Abstract][Full Text] [Related]
19. Plasma microRNAs Predict Chemoresistance in Patients With Metastatic Breast Cancer.
Shao B; Wang X; Zhang L; Li D; Liu X; Song G; Cao H; Zhu J; Li H
Technol Cancer Res Treat; 2019 Jan; 18():1533033819828709. PubMed ID: 30786836
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]